MA53446A - Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci - Google Patents

Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci

Info

Publication number
MA53446A
MA53446A MA053446A MA53446A MA53446A MA 53446 A MA53446 A MA 53446A MA 053446 A MA053446 A MA 053446A MA 53446 A MA53446 A MA 53446A MA 53446 A MA53446 A MA 53446A
Authority
MA
Morocco
Prior art keywords
collections
peptides
methods
peptide agents
peptide
Prior art date
Application number
MA053446A
Other languages
English (en)
French (fr)
Inventor
John Hanney Mcgee
Mark Joseph Mulvihill
Araghi Raheleh Rezaei
Ty Matthew Thomson
Gregory L Verdine
Sebastian Christof Theodor Wahl
Yue-Mei Zhang
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of MA53446A publication Critical patent/MA53446A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
MA053446A 2018-08-20 2019-08-20 Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci MA53446A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862719996P 2018-08-20 2018-08-20

Publications (1)

Publication Number Publication Date
MA53446A true MA53446A (fr) 2021-06-30

Family

ID=69591277

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053446A MA53446A (fr) 2018-08-20 2019-08-20 Collections de peptides, d'agents peptidiques et procédés d'utilisation de ceux-ci

Country Status (14)

Country Link
US (1) US12398178B2 (enExample)
EP (1) EP3840766A4 (enExample)
JP (1) JP2021535108A (enExample)
KR (1) KR20210060482A (enExample)
CN (1) CN113039195A (enExample)
AU (1) AU2019326423A1 (enExample)
BR (1) BR112021003113A2 (enExample)
CA (1) CA3110082A1 (enExample)
EA (1) EA202190531A1 (enExample)
IL (1) IL280931A (enExample)
MA (1) MA53446A (enExample)
MX (1) MX2021001943A (enExample)
SG (1) SG11202101672YA (enExample)
WO (1) WO2020041270A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004555A2 (pt) * 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
GB201909103D0 (en) * 2019-06-25 2019-08-07 Univ Bath Compounds
BR112023025528A2 (pt) * 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc Peptídeos grampeados e métodos destes

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US10716828B2 (en) 2007-05-02 2020-07-21 Dana-Farber Cancer Institute, Inc. Methods of modulating cellular homeostatic pathways and cellular survival
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
EP3698811A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US20130035304A1 (en) 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
AU2011274474B2 (en) 2010-07-09 2015-06-18 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
CA2833171C (en) 2011-04-15 2021-08-31 Loren D. Walensky Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
WO2012174409A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized variant maml peptides and uses thereof
CA3173988A1 (en) 2011-10-11 2013-04-18 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
WO2013102211A2 (en) 2011-12-29 2013-07-04 Walensky Loren D Stabilized antiviral fusion helices
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
CA3113959A1 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3782638A1 (en) 2013-03-13 2021-02-24 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
WO2014144148A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
WO2014201370A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
EP3270945A4 (en) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selective mcl-1 binding peptides
EP3310373A4 (en) 2015-06-22 2019-02-13 University of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
US10464975B2 (en) 2015-07-02 2019-11-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
JP7049989B2 (ja) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｆｌ－１と結合するペプチド
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
US10280317B2 (en) 2016-07-07 2019-05-07 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose
US11034720B2 (en) * 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
BR112020004555A2 (pt) 2017-09-07 2020-09-24 Fog Pharmaceuticals, Inc. agentes que modulam funções de beta-catenina e métodos dos mesmos
AU2019326423A1 (en) 2018-08-20 2021-04-08 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
CA3159729A1 (en) 2019-12-11 2021-06-17 Amrita Singh CHANDHOKE Technologies useful for assessing permeability
EP4121082A4 (en) 2020-03-17 2024-05-01 Fog Pharmaceuticals, Inc. HELICALLY STAPLED PEPTIDES AND USES THEREOF
CA3186681A1 (en) 2020-07-22 2022-01-27 Brian Halbert WHITE Stapled peptides and methods thereof
CN116113621A (zh) 2020-07-22 2023-05-12 弗格制药有限公司 氨基酸
BR112023025528A2 (pt) 2021-06-08 2024-02-27 Fog Pharmaceuticals Inc Peptídeos grampeados e métodos destes
US20240376151A1 (en) 2022-10-31 2024-11-14 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
US20260207704A1 (en) 2022-12-15 2026-07-23 Parabilis Medicines, Inc. Stapled peptides and methods thereof
WO2024130217A1 (en) 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
EA202190531A1 (ru) 2021-08-09
KR20210060482A (ko) 2021-05-26
SG11202101672YA (en) 2021-03-30
US12398178B2 (en) 2025-08-26
BR112021003113A2 (pt) 2021-05-11
US20210179665A1 (en) 2021-06-17
WO2020041270A1 (en) 2020-02-27
EP3840766A1 (en) 2021-06-30
EP3840766A4 (en) 2022-06-22
WO2020041270A9 (en) 2020-05-07
IL280931A (en) 2021-04-29
JP2021535108A (ja) 2021-12-16
CA3110082A1 (en) 2020-02-27
MX2021001943A (es) 2021-07-15
CN113039195A (zh) 2021-06-25
AU2019326423A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
EP3802617A4 (en) MULTISPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF
EP3935155A4 (en) CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE
EP3829494A4 (en) IMPLANTS, SYSTEMS AND METHODS OF USE THEREOF
EP3765023A4 (en) SYNTHETIC DNA VECTORS AND METHODS OF USE
EP3634430A4 (en) MULTIBIOTICS AND METHOD OF USING THEREFORE
EP3701066A4 (en) PROTEINIDENTIFICATION PROCEDURES AND SYSTEMS
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
EP3752166A4 (en) TRIALKYN CONNECTORS AND METHOD OF USE
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3458095A4 (en) VARIANT PD-L1 POLYPEPTIDE, T-CELL MODULATING MULTIPLE POLYPEPTIDE AND METHOD OF USE THEREOF
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
EP3980067A4 (en) ANTIBODY INTERLEUKIN FUSION PROTEIN AND METHODS OF USE
EP3436068A4 (en) BINDING PROTEINS AND METHOD FOR USE THEREOF
EP3390443A4 (en) ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
EP3849581A4 (en) DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF
EP3423438A4 (en) PLANT VIRUS MOTOR PROTEINS AND METHOD FOR USE THEREOF
EP3935079A4 (en) T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
EP3830128A4 (en) ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B-SHEDDING AND METHODS OF USE
EP3710589A4 (en) ANTI-C1S ANTIBODIES AND METHOD OF USING
EP3394098A4 (en) ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
IL280931A (en) Collections of peptides, peptide agents, and methods of use thereof
EP3880812A4 (en) ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
EP3911355A4 (en) RECOMBINANT LUBRICINS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP3802569A4 (en) CELL-PERMEABLE PEPTIDES AND METHODS OF USE THEREOF
EP4054607A4 (en) SELECTIVE HDAC6 DEGRADERS AND METHODS OF USE THEREOF